Hepatocellular Carcinoma
Conditions
Keywords
early stage HCC, TARE, SIRT, radioembolization, Holmium-166
Brief summary
166Ho-TARE is a promising modality for the treatment of HCC, given the unique characteristics of holmium, allowing careful patient selection and personalized dosimetry treatment planning. Further clinical evidence is needed to evaluate the safety and efficacy of 166Ho-TARE in the treatment of HCC patients with limited tumor burden, well preserved liver function and performance status and ineligible for liver transplantation and/or liver resection. This study will also provide further evidence on the dose-response relationship of 166Ho-TARE in (early) HCC.
Detailed description
This is a prospective, single-arm, open-label, multicenter study with 166Ho-TARE in unresectable HCC patients with limited tumor burden and well-preserved liver function and performance status, ineligible for liver transplantation and/or liver resection. Eligibility for liver transplantation and liver resection is determined by the multidisciplinary tumor board. However, patients eligible for liver transplantation can still be included in the setting of bridge to transplant. The study proposes to use 166Ho-TARE, including both therapeutic 166Ho-microspheres (QuiremSpheres™ Holmium-166 Microspheres) and scout 166Ho-microspheres (QuiremScout™ Holmium-166 Microspheres). All patients providing informed consent and meeting the selection criteria will be further screened using a scout dose of 166Ho-microspheres to evaluate 166Ho-TARE eligibility. Patients not eligible for selective 166Ho-TARE are considered screen failures and will not be considered as enrolled. The primary endpoint will be assessed by blinded, independent central review, organized by an imaging core laboratory.
Interventions
DEVICEHolmium-166 treatment
Implantation into hepatic tumors by delivery via the hepatic artery for the treatment of unresectable HCC liver tumors.
DEVICEHolmium-166 work-up
Evaluation of lung-shunt, extrahepatic deposition and intrahepatic distribution of intra-arterially injected microspheres for patients that are eligible for TARE treatment.
Sponsors
Terumo Europe N.V.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years 2. Multidisciplinary tumor board decision for locoregional treatment 3. Freely given, written informed consent 4. Patients with unresectable HCC with a single nodule ≤ 8 cm or up to three nodules with a diameter of ≤ 5 cm (each) eligible for selective radioembolization (including position changes of infusion catheters) 5. Non-cirrhotic patients or Child-Pugh A cirrhosis 6. ECOG performance status 0-1 7. Using an acceptable method of contraception throughout the study until survival follow up (for subjects of childbearing potential) 8. Adequate hematological, renal and liver function. Adequate hematological function defined as: * Hemoglobin ≥ 6 mmol/L (9.7 g/dL) * WBC ≥ 3.0 x 10E9/L * Absolute neutrophil count ≥ 1.5 x 10E9/L * Platelet count ≥ 50,000/mm3 Adequate renal function defined as: * Serum urea and serum creatinine \< 1.5 times upper limit of normal (ULN) * Creatinine clearance ≥ 45 ml/min Adequate liver function defined as: * Total bilirubin ≤ 35µmol/L (2.05 mg/dL) * Albumin ≥ 30 g/L * AST and ALT ≤ 5X ULN
Exclusion criteria
1. Diffuse and/or infiltrative HCC (defined as HCC consisting of multiple tiny liver nodules spreading throughout the entire liver or entire lobe, without a dominant nodule) 2. Hypoperfused HCC (defined as a lack of tumor blush (i.e. reduced or no uptake of contrast fluid) observed on the intra-procedural CT) 3. No full, selective arterial coverage on intra-procedural CT 4. Life expectancy \< 6 months 5. Child-Pugh score ≥7 points 6. Prior liver transplantation 7. Prior locoregional or systemic anti-cancer therapy for HCC and previous malignancies 8. Macrovascular invasion (defined as macrovascular invasion of the hepatic and/or portal vein main branches) 9. Extrahepatic metastases 10. Clinically significant ascites 11. Hepatic encephalopathy 12. Untreated active hepatitis B and/or C 13. Work-up imaging showing: * Lung shunt \> 30 Gy is simulated on 166Ho-scout imaging; or * Uncorrectable extrahepatic deposition of simulated 166Ho-scout dose activity. Activity in the falciform ligament, portal lymph nodes and gallbladder is accepted; or * Anticipated ineffective tumor targeting (\< 150 Gy mean tumor simulated absorbed dose) of 166Ho-scout for each lesion; or * Entire tumor burden not within the perfused liver volume (possible extrahepatic collateral supply of the tumor); or * Perfused liver volume \> 50% of whole liver tissue 14. Pregnant or breast-feeding 15. Current or history of cancer other than HCC, except adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix 16. In the Investigator's opinion there is a reason that could limit the patient's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study 17. Concurrently enrolled in another study, unless it is an observational non-interventional study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| confirmed Objective Response Rate (ORR) by localized mRECIST | 5 years | ORR is defined as the proportion of patients achieving either complete or partial tumor response during the study, as assessed by blinded central image review according to localized mRECIST |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Best ORR based on localized mRECIST | 5 years | The number and percent of patients with a confirmed response |
| Best and confirmed ORR based on mRECIST | 5 years | The number and percent of patients with a confirmed response |
| Duration of Response (DoR) ≥ 6 months based on localized mRECIST and mRECIST | 5 years | The number and percent of patients with a DoR ≥ 6 months. DoR is measured from time of initial response until radiological progression. Radiological progression is determined by blinded central image review according to localized mRECIST and mRECIST. |
| Time to Progression (TTP) | 5 years | TTP defined as the time from treatment with QuiremSpheresTM Holmium-166 Microspheres to progression as per mRECIST |
| Progression-Free Survival (PFS) | 5 years | PFS defined as the time from treatment with QuiremSpheresTM Holmium-166 Microspheres to the date of radiological progression or death from any cause. Radiological progression is determined by blinded central image review according to mRECIST |
| hepatic Progression-Free Survival (hPFS) | 5 years | hPFS defined as the time from treatment with QuiremSpheresTM Holmium-166 Microspheres to the date of radiological progression in the liver or death from any cause. Radiological progression is determined by blinded central image review according to mRECIST |
| Liver transplantation rate | 5 years | The number and percent of patients receiving a liver transplant |
| Assessment of dosimetry and biodistribution based on quantitative assessment of imaging scans | 5 years | Correlation between scout and treatment for extrahepatic dose deposition, including lung shunt and digestive shunting of QuiremSpheresTM Holmium-166 Microspheres. |
| Overall survival (OS) | 5 years | The median overall survival time |
| Safety and toxicity by evaluating the number of adverse events and the number of patients with each event | 5 years | Adverse events classified by Common Terminology Criteria for Adverse Events (CTCAE) v5.0. (including clinical and laboratory toxicity) |
| Liver function during follow-up ALBI score | 5 years | ALBI score |
| Liver function during follow-up using MELD score | 5 years | MELD score |
| Liver function during follow-up using Child Pugh score | 5 years | Child Pugh score |
| Quality of Life using EQ-5D-5L questionnaire | 1 year | Patient reported outcome using EQ-5D-5L questionnaire. The scale measures quality of life on a 5-component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. |
| Liver resection rate | 5 years | The number and percent of patients undergoing a liver resection |
Countries
Germany
Outcome results
None listed